AIM ImmunoTech Inc. — Director's Dealing 2025

Mar 6, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AIM ImmunoTech Inc. (AIM)
CIK: 0000946644
Period of Report: 2025-03-05

Reporting Person: Equels Thomas K (Director, CEO & President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-03-05	Common Stock	P	50000	$0.1346	Acquired	1858029	Direct